Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 - Episode 7
Understanding HER2 Testing in BTC: Detection and Clinical Approaches
Panelists discuss how molecular testing strategies at disease progression are evolving in biliary tract cancer (BTC), with particular focus on HER2-amplification detection methods including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS), while noting that HER2 positivity occurs in approximately 5% to 15% of cases.
- Switching gears to BTC patients with disease progression requiring subsequent therapy, do you reperform biomarker testing at disease progression?
- How prevalent is HER2 amplification in BTC? How can HER2 amplification be detected and which techniques are you utilizing in your clinical practice (IHC, FISH, or NGS)?
- Please comment on any other important nuances to HER2 testing.
Related Content:
